Skip to the content
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact

The landscape of antibody binding in SARS-CoV-2 infection

  • Scientific Publication
  • June 18, 2021
  • Scientific Publication
  • June 18, 2021

Heffron AS, McIlwain SJ, Amjadi MF, Baker DA, Khullar S, et al. (2021) The landscape of antibody binding in SARS-CoV-2 infection. PLOS Biology 19(6): e3001265. https://doi.org/10.1371/journal.pbio.3001265

Abstract

The search for potential antibody-based diagnostics, vaccines, and therapeutics for pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused almost exclusively on the spike (S) and nucleocapsid (N) proteins. Coronavirus membrane (M), ORF3a, and ORF8 proteins are humoral immunogens in other coronaviruses (CoVs) but remain largely uninvestigated for SARS-CoV-2. Here, we use ultradense peptide microarray mapping to show that SARS-CoV-2 infection induces robust antibody responses to epitopes throughout the SARS-CoV-2 proteome, particularly in M, in which 1 epitope achieved excellent diagnostic accuracy. We map 79 B cell epitopes throughout the SARS-CoV-2 proteome and demonstrate that antibodies that develop in response to SARS-CoV-2 infection bind homologous peptide sequences in the 6 other known human CoVs. We also confirm reactivity against 4 of our top-ranking epitopes by enzyme-linked immunosorbent assay (ELISA). Illness severity correlated with increased reactivity to 9 SARS-CoV-2 epitopes in S, M, N, and ORF3a in our population. Our results demonstrate previously unknown, highly reactive B cell epitopes throughout the full proteome of SARS-CoV-2 and other CoV proteins.

PrevPrevious
NextNext
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • CONNECT ON LINKEDIN

Copyright © 2024 Nimble Therapeutics, Inc